-
1.发明授权公开(公告)号：US10052360B2
公开(公告)日：2018-08-21
申请号：US15047849
申请日：2016-02-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: C07K14/705 , A61K38/17 , A61K39/00 , A61K39/395 , A61K47/48 , A61K38/00
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
-
公开(公告)号：US09012408B2
公开(公告)日：2015-04-21
申请号：US13851166
申请日：2013-03-27
Applicant: Bristol-Myers Squibb Company
Inventor： George Vratsanos , Jean-Claude Becker , Michael Corbo
IPC: A61K38/16 , C07K16/28 , C07K14/705 , A61K38/00
CPC classification number: C07K16/2827 , A61K38/00 , C07K14/70521 , C07K2319/30
Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
-
3.发明授权Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule 有权通过施用可溶性CTLA4分子治疗幼年类风湿性关节炎的方法公开(公告)号：US08703718B2
公开(公告)日：2014-04-22
申请号：US13795545
申请日：2013-03-12
Applicant: Bristol-Myers Squibb Company
Inventor： Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: A61K38/16
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫性疾病如青少年类风湿性关节炎的组合物和方法。
-
Patent Agency Ranking
4.发明申请METHOD OF PREVENTING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS WITH UNDIFFERENTIATED ARTHRITIS 审中-公开防止患有炎症性疾病的受试者中炎性角膜炎发展的方法公开(公告)号：US20130195865A1
公开(公告)日：2013-08-01
申请号：US13851166
申请日：2013-03-27
Applicant: Bristol-Myers Squibb Company
Inventor： George Vratsanos , Jean-Claude Becker , Michael Corbo
IPC: C07K16/28 , C07K14/705
CPC classification number: C07K16/2827 , A61K38/00 , C07K14/70521 , C07K2319/30
Abstract: The invention relates to methods and compositions for treating undifferentiated arthritis (UA) and/or preventing the development of rheumatoid arthritis (RA) in subjects with UA by administering to a subject in need thereof an effective amount of soluble CTLA4 molecule.
Abstract translation: 本发明涉及通过向有需要的受试者施用有效量的可溶性CTLA4分子来治疗未分化关节炎（UA）和/或预防UA患者类风湿性关节炎（RA）发展的方法和组合物。
-
5.发明申请METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE 审中-公开通过管理可溶性CTLA4分子来治疗SCLERODERMA的方法公开(公告)号：US20160158318A1
公开(公告)日：2016-06-09
申请号：US15047849
申请日：2016-02-19
Applicant: Bristol-Myers Squibb Company
Inventor： Robert COHEN , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫性疾病的组合物和方法。
-
6.发明授权Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule 有权通过施用可溶性CTLA4分子治疗干燥综合征的方法公开(公告)号：US08722632B2
公开(公告)日：2014-05-13
申请号：US13788970
申请日：2013-03-07
Applicant: Bristol-Myers Squibb Company
Inventor： Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: A61K38/16
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫疾病如干燥综合征的组合物和方法。
-
7.发明授权Methods for treating scleroderma by administering a soluble CTLA4 molecule 有权通过施用可溶性CTLA4分子治疗硬皮病的方法公开(公告)号：US09296808B2
公开(公告)日：2016-03-29
申请号：US14193687
申请日：2014-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: C07K14/705 , A61K39/395 , A61K38/00 , A61K39/00
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫疾病如硬皮病的组合物和方法。
-
8.发明申请METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE 审中-公开通过管理可溶性CTLA4分子来治疗SCLERODERMA的方法公开(公告)号：US20140286948A1
公开(公告)日：2014-09-25
申请号：US14193687
申请日：2014-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Robert COHEN , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
IPC: C07K14/705
CPC classification number: A61K38/1774 , A61K38/00 , A61K39/0008 , A61K39/395 , A61K47/6811 , C07K14/70521 , C07K2319/00
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Abstract translation: 本发明涉及通过向受试者施用阻断内源性B7分子结合其配体的CTLA4分子来治疗自身免疫性疾病如硬皮病的组合物和方法。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.025 seconds)
